Using radioactive iodide 125 in uveal melanoma

Evaluation of the efficacy of radioactive iodide 125 made in Iran in uveal melanoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016091929875N1

Enrollment

Registered

2016-10-05

Start date

2016-09-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uveal melanoma. Choroid

Interventions

This intervention will be undertaken as implantation of Iodide radioactive plaque under the ocular tumor on sclera, for a measured time, according to the thickness of the tumor. After this period of

Treatment - Devices

This intervention will be undertaken as implantation of Iodide radioactive plaque under the ocular tumor on sclera, for a measured time, according to the thickness of the tumor. After this period of

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: INCLUSION: All the patients with uveal melanoma that are not the candidates for ruthenium plaques and un-acception of the enucleation by the patient. Exclusion: Unwillingness of the patient for continuing the study, pregnancy and nursing.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Decrease in the thickness of tumor. Timepoint: At 4 months. Method of measurement: ultrasound and clinical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFariba Ghassemi

Tehran University of Medical Sciences

ghasemi_f@sina.tums.ac.ir+98 21 5540 0010

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026